MAPK1 and non-small cell lung carcinoma: Somatic mutations in MEK1 gene that affect the MAPK/ERK pathway were described in <1 % of non-small cell lung cancer (NSCLC) and they are more commonly reported in adenocarcinoma than squamous cell carcinoma, smokers or former smokers, and their presence was not associated with age, gender, race or disease stage [2, 7–10].